Company Filing History:
Years Active: 2016-2025
Title: James P. Allison: Pioneering Cancer Research through Innovative Patents
Introduction
James P. Allison is a prominent inventor and researcher based in Houston, TX (US). He is renowned for his groundbreaking work in cancer immunotherapy, which has significantly advanced the treatment of metastatic cancer. With a total of 3 patents, Allison's contributions to the field are both innovative and impactful.
Latest Patents
Allison's latest patents include significant advancements in cancer treatment methodologies. One of his notable patents is for "Antibodies to human B7x for treatment of metastatic cancer." This patent outlines methods for treating metastatic cancer in patients by administering an antibody to B7x, or an active antibody fragment that binds B7x, in an effective amount to treat or prevent metastasis. Another important patent is for "LILRB4-binding antibody and methods of use thereof." This patent provides LILRB4-binding antibodies and methods for treating cancer, either alone or in combination with other therapies. Additionally, it includes recombinant polypeptides comprising the CDRs of LILRB4-binding antibodies.
Career Highlights
Throughout his career, James P. Allison has made significant contributions to cancer research. He has worked at esteemed institutions such as the Albert Einstein College of Medicine and the Sloan Kettering Institute for Cancer Research. His work has not only advanced scientific understanding but has also led to practical applications in cancer treatment.
Collaborations
Allison has collaborated with notable colleagues in the field, including Xingxing Zang and Naveen Sharma. These collaborations have further enriched his research and contributed to the development of innovative cancer therapies.
Conclusion
James P. Allison's work exemplifies the intersection of innovation and medical research. His patents and career achievements have made a lasting impact on cancer treatment, paving the way for future advancements in the field.